Navigation Links
Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
Date:7/10/2012

FARMINGTON, Conn., July 10, 2012 /PRNewswire-iReach/ -- More companies are investing in kinase inhibitor research to address issues such as resistance, selectivity versus safety, developing lead compounds, and integrating chemistry and biology into development, as well as utilizing the latest technologies and techniques such as fragment- and structure-based design to develop new products. Having accurate market data and analysis is essential to companies that wish to compete on the global stage. With premium market research from the world's leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and analyses.

(Photo: http://photos.prnewswire.com/prnh/20120710/CG37789)

Global Information is pleased to announce the immediate availability of three significant new reports on Kinase Inhibitors.

Kinase Inhibitors: Global Markets -- Focus on Europe

Kinase Inhibitors: Global Markets -- Focus on US

Kinase Inhibitors: Global Markets -- Focus on Emerging Markets

The overall goal of this series is to provide a comprehensive understanding of the current and future characteristics for kinase inhibitors, which include tyrosine inhibitors, multi-target kinase inhibitors, serine/threonine inhibitors and monoclonal antibody kinase inhibitors.

Each report offers market sizes with sales and revenues figures from 2011 to 2016 for kinase inhibitors in the pharmaceutical and biotechnology industry. Market projections, market shares and a technology SWOT analysis are also included.

Global revenues for kinase inhibitors were nearly $29.1 billion in 2011 and are projected to reach nearly $40.3 billion in 2015 at a five-year compound annual growth rate (CAGR) of 6.7%. The kinase inhibitors market is witnessing an increasing number of novel kinase inhibitors being utilized in human trials, particularly in the development of next-generation inhibitors that target cancers and other disease, including inflammation.

The United States kinase inhibitor market accounted for $10.4 billion in 2011 and is expected to reach $11.6 billion by 2016 at a CAGR of 2.2%. Monoclonal antibody kinase inhibitors in the U.S. market brought in $7.6 billion in 2010 and came down to $6.6 billion in 2011. This segment is expected to continue on a downward trend at a CAGR of -4% to reach $5.4 billion in 2016.

Strong growth is expected in the emerging markets segment for kinase inhibitors, which reached $2.9 billion in 2010 and $4.1 billion in 2011 and is expected to post $8.4 billion by 2016 at a CAGR of 15.2%. Antibody kinase inhibitors in the emerging markets segment is expected to reach $4.3 billion by 2016.

An Executive Summary of this analysis and a free sample of each report is available from Global Information, Inc:

Emerging Markets
http://www.giiresearch.com/report/bc246348-kinase-inhibitors-global-markets-focus-on-emerging.html

US Markets
http://www.giiresearch.com/report/bc246349-kinase-inhibitors-global-markets-focus-on-us.html

European Markets
http://www.giiresearch.com/report/bc246350-kinase-inhibitors-global-markets-focus-on-europe.html

BCC Research provides a multitude of studies on the Biotechnology markets. Topics range from stem cells to enzyme inhibitors and drug discovery technologies. Each report analyzes the market along with its applications, regulatory environment, technology, market projections and market share. Discover more at http://www.giiresearch.com/publisher/BC/biotechnology.shtml

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp  

News distributed by PR Newswire iReach: https://ireach.prnewswire.com



'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
2. Global Angiogenesis Inhibitors and Stimulators Industry
3. Global Markets for Enzyme Inhibitors
4. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
5. United States Market for Psoriatic Arthritis Pharmacotherapy
6. Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
7. Analysis of the North American Radiology Image and Information Management Systems Market
8. Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
9. North America ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
10. Middle East and Africa Surgical Equipment Market Outlook to 2018 -Electrosurgical Devices, Hand Instruments and Surgical Sutures
11. Medical Diagnostic & Therapeutic Ultrasound Devices Market (2012 - 2017) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... July 21, 2017  Endo International plc (NASDAQ: ... comprehensive review of its manufacturing network, the Company will ... facilities in Huntsville, Alabama . The ... over the next 12 to 18 months. The ... declining volumes of commoditized products and these restructuring actions ...
(Date:7/19/2017)... , July 19, 2017  Mako Medical Laboratories partnered ... the Military Family Assistance Fund (MFA) to bring 140 ... to visit with their families one last time before ... coordinate the travel and logistics needed for these soldiers. ... soldiers and their families. We just wish we could ...
(Date:7/14/2017)... -- Endo International plc (NASDAQ: ENDP ) will announce ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 45397076. Please dial in 10 minutes prior to ... A replay of the call will be available from August 8, ...
Breaking Medicine Technology:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Winner for its Product Innovation in the prestigious CEO World Awards®. The coveted ... performance, new products and services, CEO case studies, corporate social responsibility, and milestones ...
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South Austin is ... 24 Hours a day. , The Emergency Room opened early March, ... open four months now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency ...
(Date:7/24/2017)... PARK (PRWEB) , ... July 24, 2017 , ... Engineers ... is bio-compatible, because it produces the same kind of electrical energy that the body ... the form of moving electrons. This flow of electrons out of the battery is ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P ... of the new Destination Medical Building located at Mayo Clinic in Jacksonville, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
Breaking Medicine News(10 mins):